3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
149
Breast Neoplasms
87
Colorectal Neoplasms
64
Neoplasms
53
Pancreatic Neoplasms
52
Lung Neoplasms
49
Neoplasm Metastasis
45
Stomach Neoplasms
43
Ovarian Neoplasms
42
Rectal Neoplasms
41
Esophageal Squamous Cell Carcinoma
34
Esophageal Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
30
Head and Neck Neoplasms
30
Leukemia, Myeloid, Acute
28
Recurrence
24
Triple Negative Breast Neoplasms
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Glioblastoma
21
Uterine Cervical Neoplasms
20
Small Cell Lung Carcinoma
20
Nasopharyngeal Carcinoma
20
Fallopian Tube Neoplasms
19
Lymphoma, Non-Hodgkin
18
Lymphoma
18
Colonic Neoplasms
17
Prostatic Neoplasms
16
Leukemia
15
Carcinoma, Ovarian Epithelial
15
Melanoma
14
Interventions
Gemcitabine
6
Fluorouracil
5
Leucovorin
4
Irinotecan
3
Albumin-Bound Paclitaxel
3
pembrolizumab
2
irinotecan sucrosofate
2
Oxaliplatin
2
4-fluorobenzoyl-TN-14003
2
zolbetuximab
1
regorafenib
1
olaparib
1
ibrutinib
1
beta-D-glucosylisophosphoramide mustard
1
adavosertib
1
Tetrahydrouridine
1
Telemedicine
1
Taxes
1
Practice Guidelines as Topic
1
Paclitaxel
1
PEGPH20
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Docetaxel
1
Decitabine
1
Counseling
1
Cisplatin
1
Capecitabine
1
BKT140
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Pancreatic Adenocarcinoma
×
Drug Therapy
×
Clear all
NCT02826486
2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2
Completed
80 enrolled
13 charts